Management of High Risk Locally Advanced Prostate Cancer
摘要
A multimodal strategy remains the backbone of treatment for patients with HRLAPC. RP (in a multimodal approach) and long-term ADT with EBRT are currently recommended as first-line treatments. Initial tumor characteristics (GS, T stage) and the toxicity profiles of the treatments should be part of the decision. Patients should be well informed on the basis of current data and possibly included in RCTs.